**Agenda**

7:30–7:40am **Program Overview and Objectives**  
*Peter Greenberg, MD*  
Stanford Cancer Institute

7:40–8:15am **Update of WHO and Molecular Classifications in MDS**  
*Mario Cazzola, MD*  
University of Pavia

8:15–8:50am **Therapeutic and Prognostic Role of Epigenetic Abnormalities in MDS**  
*Stephen Nimer, MD*  
Sylvester Cancer Center, U Miami

8:50–9:25am **Current Results of Alternative Conditioning Regimens and Donors for Allogeneic Hematopoietic Stem Cell Transplantation in MDS**  
*H. Joachim Deeg, MD*  
Fred Hutchinson Cancer Research Center

9:25–10:00am **Impact of Comorbidity on Quality of Life and Clinical Outcomes in MDS**  
*Peter Valent, MD*  
Medical University of Vienna

10:00–10:35am **Myeloid-derived Suppressor Cells and Altered Innate Immunity: Contribution to MDS Pathogenesis**  
*Alan List, MD*  
Moffitt Cancer Center, Tampa, FL

10:35–11:00am **Questions/Answers/Discussion**
About the Foundation

Who Are We?
The Myelodysplastic Syndromes Foundation, Inc. was established in 1994 by an international group of physicians and researchers to provide education about MDS to physicians and patients, support for MDS research, patient support and advocacy.

JOIN US AS AN MDS CENTER OF EXCELLENCE

Apply for The Centers of Excellence Program:
Would you like your treatment center to become part of the Foundation’s research network and referral system for MDS patients?
Please call us for more information and an application.
MDS Foundation:
National & International Focus

- Patient/Family resources
- Health care professional resources
MDS Foundation

• Patient/Family resources
  – Patient, caregiver forums
  – MDS informational booklets/translations
  – Global patient support groups
    • MDS Alliance: Patient group coalition
  – Insurance & reimbursement information
  – Clinical trial information
MDS Foundation

• Health care professional resources/projects
  – Collaborative international scientific board members
  – International Nursing Leadership Group
  – MDSF Center of Excellence referrals/webinars
  – Young Investigator research grants
  – Informational materials
    • Building Blocks of Hope/100 Q&A re MDS
    • MDSF Newsletter/Updated MDS bibliographies
  – IWG-PM Clinical & Molecular Collaborations
  – ASH & International Scientific/Educational Symposia
The Taub Foundation Grants Program for MDS Research was created to support high-impact, innovative translational research to understand the underlying causes of MDS and to advance its treatment and prevention. The Program specifically focuses on MDS research, exclusive of AML and MPN.

Eligibility:
• All applicants must hold a faculty appointment at a non-profit, academic, medical, or research institution in the United States.
• United States citizenship is not required; visa documentation is not required.
• Only one application may be submitted per PI.

Join the RFA Mailing List:
Please contact EJohnstone@hria.org or call 617-279-2240 ext. 710
Advancing Research & Patient Care

THE 13th INTERNATIONAL SYMPOSIUM ON
MYELODYSPLASTIC SYNDROMES


www.kenes.com/mds
Thank you to our supporters!

This activity is supported by educational grants from:

Baxter Healthcare Corporation
Celgene Corporation
Onconova Therapeutics
1. Iron overload in MDS is prognostic and:
   a. Correlates with a poor overall survival
   b. Correlates with certain comorbidities
   c. Should be corrected before stem cell transplantation
   d. a, b and c

2. In the context of MDS, fatigue is:
   a. Rarely seen
   b. Frequently recorded
   c. Often found in those who have comorbidities
   d. b and c
3. Myeloid-derived suppressor cells (MDSC) are a phenotypically distinct innate immune effector cell that displays high expression of which of the following antigens?
   a. CD34
   b. CD33
   c. CD14

4. Bone marrow-MDSC are markedly expanded in MDS and are responsible for which of the following?
   a. Cell death of hematopoietic progenitors
   b. Suppression of anti-tumor immune response
   c. Elaboration of inflammatory cytokines
   d. All of the above
5. Which factors determine primarily the incidence of relapse after HCT for MDS?
   a. Transfusions given before HCT
   b. Marrow myeloblast count
   c. Cytogenetics
   d. Pre-transplant therapy
   e. b and c

6. Which would be your order of priority in selecting a transplant donor?
   a. HLA-matched (HLA=) sibling > HLA= unrelated donor (URD) > HLA haplo-identical relative > cord blood
   b. HLA= sibling > HLA= URD > cord blood > HLA haplo-identical relative
   c. HLA= sibling > HLA haplo-identical relative > HLA= URD > cord blood
   d. HLA= sibling > cord blood > HLA=URD > HLA haplo-identical relative
Pre-Test

7. Somatic mutations in one of the following genes of RNA splicing machinery are associated with an MDS subtype with distinct phenotype and indolent clinical course. Which is the gene?
   a. SF3B1
   b. SRSF2
   c. U2AF1

8. More than 90% of patients with chronic myelomonocytic leukemia carry somatic mutations of genes of various biologic pathways. Many of them have concomitant mutations in 2 genes: which is the typical co-mutation of CMML?
   a. SF3B1-JAK2
   b. TET2-SRSF2
   c. CSF3R-SETBP1
9. The presence of TET2 mutations predicts for:
   a. Worse survival in MDS patients
   b. A worse response to hypomethylating agents
   c. A lower than normal platelet count
   d. None of the above

10. DNA methylation patterns predict for:
    a. A worse survival in patients with RAEB-I
    b. Response to decitabine or 5-azacytidine
    c. The presence of specific mutations within the MDS genome
    d. Clonal diversity at diagnosis in MDS patients
Agenda

7:30–7:40am  Program Overview and Objectives
Peter Greenberg, MD

7:40–8:15am  Update of WHO and Molecular Classifications in MDS
Mario Cazzola, MD

8:15–8:50am  Therapeutic and Prognostic Role of Epigenetic Abnormalities in MDS
Stephen Nimer, MD

8:50–9:25am  Current Results of Alternative Conditioning Regimens and Donors for Allogeneic Hematopoietic Stem Cell Transplantation in MDS
H. Joachim Deeg, MD

9:25–10:00am  Impact of Comorbidity on Quality of Life and Clinical Outcomes in MDS
Peter Valent, MD

10:00–10:35am  Myeloid-derived Suppressor Cells and Altered Innate Immunity: Contribution to MDS Pathogenesis
Alan List, MD

10:35–11:00am  Questions/Answers/Discussion